TRCT
BLACU

Tower Research Capital (TRC)’s Bellevue Life Sciences Acquisition Corp. Unit BLACU Stock Holding History

Tower Research Capital (TRC)’s Portfolio BLACU Stock Details BLACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$116 – 6010
2024
Q4 		$116 Hold
10
– – ﹤0.01% 5450
2024
Q3 		$110 Hold
10
– – ﹤0.01% 5505
2024
Q2 		$109 Hold
10
– – ﹤0.01% 5480
2024
Q1 		$110 Hold
10
– – ﹤0.01% 5647
2023
Q4 		$106 Hold
10
– – ﹤0.01% 5708
2023
Q3 		$108 Hold
10
– – ﹤0.01% 5719
2023
Q2 		$108 Hold
10
– – ﹤0.01% 5812
2023
Q1 		$0 Buy
+10
New +$102 ﹤0.01% 6399

Tower Research Capital (TRC)'s BLACU Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of Bellevue Life Sciences Acquisition Corp. Unit (BLACU) in Q1 2025, closing a stake of 10 shares — an estimated $116 sold.

Tower Research Capital (TRC) first reported a position in BLACU in Q1 2023 and held it in 8 quarters. The position peaked at $116 in Q4 2024. 0 funds tracked by Wall St. Rank hold BLACU as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining Bellevue Life Sciences Acquisition Corp. Unit position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 10 Bellevue Life Sciences Acquisition Corp. Unit shares in Q1 2025, an estimated $116.
  • Tower Research Capital (TRC) first reported a position in Bellevue Life Sciences Acquisition Corp. Unit in Q1 2023 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s Bellevue Life Sciences Acquisition Corp. Unit position peaked at $116 in Q4 2024.
  • 0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Unit as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.